Explore the vast range of titles available.

Neurological diseases are destructive, mainly characterized by the failure of endogenous repair, the inability to recover tissue damage, resulting in the increasing loss of cognitive and physical function. Although some clinical drugs can alleviate the progression of these diseases, but they lack therapeutic effect in repairing tissue injury and rebuilding neurological function. More and more studies have shown that cell therapy has made good achievements in the application of nerve injury. Olfactory ensheathing cells (OECs) are a special type of glial cells, which have been proved to play an important role as an alternative therapy for neurological diseases, opening up a new way for the treatment of neurological problems. The functional mechanisms of OECs in the treatment of neurological diseases include neuroprotection, immune regulation, axon regeneration, improvement of nerve injury microenvironment and myelin regeneration, which also include secreted bioactive factors. Therefore, it is of great significance to better understand the mechanism of OECs promoting functional improvement, and to recognize the implementation of these treatments and the effective simulation of nerve injury disorders. In this review, we discuss the function of OECs and their application value in the treatment of neurological diseases, and position OECs as a potential candidate strategy for the treatment of nervous system diseases.

Polymerase chain reaction (PCR) is limited by the long reaction time for point-of-care. Currently, commercial benchtop rapid PCR requires 30–40 min, and this time is limited by the absence of rapid and stable heating and cooling platforms rather than the biochemical reaction kinetics. This study develops an ultrafast PCR (<3 min) platform using flow-through microchannel chips. An actin gene amplicon with a length of 151 base-pairs in the whole genome was used to verify the ultrafast PCR microfluidic chip. The results demonstrated that the channel of 56 μm height can provide fast heat conduction and the channel length should not be short. Under certain denaturation and annealing/extension times, a short channel design will cause the sample to drive slowly in the microchannel with insufficient pressure in the channel, causing the fluid to generate bubbles in the high-temperature zone and subsequently destabilizing the flow. The chips used in the experiment can complete 40 thermal cycles within 160 s through a design with the 56 µm channel height and with each thermal circle measuring 4 cm long. The calculation shows that the DNA extension speed is ~60 base-pairs/s, which is consistent with the theoretical speed of the Klen Taq extension used, and the detection limit can reach 67 copies. The heat transfer time of the reagent on this platform is very short. The simple chip design and fabrication are suitable for the development of commercial ultrafast PCR chips.

The mechanism of neuropathic pain induced by nerve injury is complex and there are no effective treatment methods. P2X4 receptor expression is closely related to the occurrence of pain. Schwann cells (SCs) play a key protective role in the repair of peripheral nerve injury and myelin sheath regeneration. However, whether SCs can affect the expression of P2X4 receptor and play a role in pathological pain is still unclear. Therefore, this study investigated the effect of SCs on whether they can down regulate the expression of P2X4 receptor to affect pain. The results showed that in the neuropathic pain induced by sciatic nerve injury model, the expression of P2X4 receptor in spinal cord tissue was significantly increased and the pain sensation of rats was increased. While SCs transplantation could down regulate the expression of P2X4 receptors in spinal cord and increase the mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL) of rats. These data indicate that SCs can reduce the expression of P2X4 receptors to alleviate neuropathic pain, indicating that SCs can mediate P2X4 receptor signalling as a new target for pain treatment.

The DNA interaction potency of a chemical has been defined in the present study as the degree of a chemical's ability to interact with DNA. An estimation method of such a potency has been established based on the peak reduction of an oligonucleotide probe resulting from its interaction with chemicals based on high-performance liquid chromatography. A DNA interaction potency equivalency (PEQ) also has been proposed to evaluate the relative interaction potency of test chemicals against benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE). Five known direct DNA interaction chemicals were employed to demonstrate the method. Two known inactive chemicals were used as negative controls. Both the potency and PEQ(50) values (PEQ of testing chemical at 50% of the probe peak reduction) of these five chemicals were determined as BPDE > phenyl glycidyl ether (PGE) > tetrachlorohydroquinone (Cl4HQ) > methyl methanesulfonate (MMS) > styrene-7,8-oxide (SO). Among the reactive chemicals, MMS was found to break the oligonucleotide into smaller fragments, whereas BPDE, PGE, and SO form covalent adducts with the oligonucleotide. In the latter case, the formation of multi-chemical–oligonucleotide adducts also was observed by mass spectrometry. The method was employed to estimate the DNA interaction potency equivalency of diesel vehicle exhaust gas to demonstrate the applicability of this approach in evaluating the interaction potency of environmental pollutants in both gas and liquid phases.

The DNA interaction potency of a chemical has been defined in the present study as the degree of a chemical's ability to interact with DNA. An estimation method of such a potency has been established based on the peak reduction of an oligonucleotide probe resulting from its interaction with chemicals based on high-performance liquid chromatography. A DNA interaction potency equivalency (PEQ) also has been proposed to evaluate the relative interaction potency of test chemicals against benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE). Five known direct DNA interaction chemicals were employed to demonstrate the method. Two known inactive chemicals were used as negative controls. Both the potency and PEQ(50) values (PEQ of testing chemical at 50% of the probe peak reduction) of these five chemicals were determined as BPDE > phenyl glycidyl ether (PGE) > tetrachlorohydroquinone (Cl4HQ) > methyl methanesulfonate (MMS) > styrene-7,8-oxide (SO). Among the reactive chemicals, MMS was found to break the oligonucleotide into smaller fragments, whereas BPDE, PGE, and SO form covalent adducts with the oligonucleotide. In the latter case, the formation of multi-chemical–oligonucleotide adducts also was observed by mass spectrometry. The method was employed to estimate the DNA interaction potency equivalency of diesel vehicle exhaust gas to demonstrate the applicability of this approach in evaluating the interaction potency of environmental pollutants in both gas and liquid phases.

Rice panicle architecture determines the grain number per panicle and therefore impacts grain yield. The OsER1–OsMKKK10–OsMKK4–OsMPK6 pathway shapes panicle architecture by regulating cytokinin metabolism. However, the specific upstream ligands perceived by the OsER1 receptor are unknown. Here, we report that the EPIDERMAL PATTERNING FACTOR (EPF)/EPF-LIKE (EPFL) small secreted peptide family members OsEPFL6, OsEPFL7, OsEPFL8, and OsEPFL9 synergistically contribute to rice panicle morphogenesis by recognizing the OsER1 receptor and activating the mitogen-activated protein kinase cascade. Notably, OsEPFL6 , OsEPFL7 , OsEPFL8 , and OsEPFL9 negatively regulate spikelet number per panicle, but OsEPFL8 also controls rice spikelet fertility. A osepfl6 osepfl7 osepfl9 triple mutant had significantly enhanced grain yield without affecting spikelet fertility, suggesting that specifically suppressing the OsEPFL6–OsER1, OsEPFL7–OsER1, and OsEPFL9–OsER1 ligand–receptor pairs can optimize rice panicle architecture. These findings provide a framework for fundamental understanding of the role of ligand–receptor signaling in rice panicle development and demonstrate a potential method to overcome the trade-off between spikelet number and fertility. Rice panicle architecture dominates grain yield. In this study, the authors demonstrate a method for rationally overcoming the trade-off between yield traits and optimizing rice panicle architecture by specifically manipulating ligand–receptor pairs.

Abstract Context Younger onset of type 2 diabetes (T2D) was associated with higher risks of vascular complications and mortality. Objective To prospectively assess risk profiles for incident T2D stratified by age at onset. Methods A total of 471 269 participants free of T2D at baseline were included from the UK Biobank. Approximately 70 clinical, lipid, lipoprotein, inflammatory, and metabolic markers, and genetic risk scores (GRSs) were analyzed. Stratified Cox proportional-hazards regression models were used to estimate hazard ratios (HRs) for T2D with age of diagnosis divided into 4 groups (≤50.0, 50.1-60.0, 60.1-70.0, and >70.0 years). Results During 11 years of follow-up, 15 805 incident T2D were identified. Among clinical risk factors, obesity had the highest HR at any age, ranging from 13.16 (95% CI, 9.67-17.91) for 50.0 years and younger to 4.13 (3.78-4.51) for older than 70.0 years. Other risks associated with T2D onset at age 50.0 years and younger included dyslipidemia (3.50, 2.91-4.20), hypertension (3.21, 2.71-3.80), cardiovascular disease (2.87, 2.13-3.87), parental history of diabetes (2.42, 2.04-2.86), education lower than college (1.89, 1.57-2.27), physical inactivity (1.73, 1.43-2.10), smoking (1.38, 1.13-1.68), several lipoprotein particles, inflammatory markers, liver enzymes, fatty acids, amino acids, as well as GRS. Associations of most risk factors and biomarkers were markedly attenuated with increasing age at onset (P interaction <.05), and some were not significant for onset at age older than 70.0 years, such as smoking, systolic blood pressure, and apolipoprotein B. Conclusion Most risk factors or biomarkers had stronger relative risks for T2D at younger ages, which emphasizes the necessity of promoting primary prevention among younger individuals. Moreover, obesity should be prioritized.

Background Individuals with frailty are at increased risk of type 2 diabetes (T2D), but the underlying mechanisms are unclear. We aimed to investigate whether the frailty-T2D association is mediated by alterations in the metabolome and assess potential interaction with genetic susceptibility to diabetes. Methods This retrospective analysis, using data from a large prospective population-based cohort, included a total of 197,502 adults with baseline metabolomics data from the UK Biobank. Frailty was defined using the Fried frailty phenotype according to five components. Elastic net regression was applied to create a frailty-related metabolic signature. We assessed hazard ratios (HR) and its 95% confidence interval (CI) of incident T2D in relation to the baseline metabolic signature of frailty and examined the mediating role of the metabolic signature in the effect of frailty on T2D. Additive interaction between the metabolic signature and polygenic risk score for T2D (PRS-T2D) on the incidence of T2D was assessed as relative excess risk due to interaction (RERI). Results Compared with non-frailty, the HR (95% CI) of incident T2D in pre-frailty and frailty was 1.33 (1.26, 1.40) and 1.59 (1.46, 1.74), respectively. The metabolic signature of frailty (comprised of 53 metabolites) was positively associated with T2D risk (HR per standard deviation increment: 1.45; 95% CI: 1.42, 1.48), and explained 31.0% (95% CI: 25.8, 36.8) of the association between frailty and T2D. An additive interaction between metabolic signature of frailty and PRS-T2D was found (RERI: 9.43; 95% CI: 6.06, 12.80). Conclusions The increased risk of T2D in individuals with frailty may be mediated through effects on the metabolome, and the influence of such metabolic alterations on diabetes risk may be amplified in individuals with genetic susceptibility to T2D. Graphical abstract

Soil alkalinization and global warming are predicted to pose major challenges to agriculture in the future, as they continue to accelerate, markedly reducing global arable land and crop yields 1 , 2 . Therefore, strategies for future agriculture are needed to further improve globally cultivated, relatively high-yielding Green Revolution varieties (GRVs) derived from the SEMIDWARF 1 ( SD1 ) gene 3 , 4 . Here we propose that precise regulation of the phytohormone gibberellin (GA) to optimal levels is the key to not only confer alkali–thermal tolerance to GRVs, but also to further enhance their yield. Endogenous modulation of ALKALI-THERMAL TOLERANCE 1/2  ( ATT1/2 ), quantitative trait loci encoding GA20-oxidases or exogenous application of GA minimized rice yield loss affected by sodic soils. Mechanistically, high GA concentrations induce reactive oxygen species over-accumulation, whereas low GA concentrations repress the expression of stress-tolerance genes by means of DELLA–NGR5-mediated H3K27me3 methylation. We further showed that ATT1 induces large fluctuations in GA levels, whereas ATT2 is the ideal candidate for fine-tuning GA concentrations to appropriate levels to balance reactive oxygen species and H3K27me3 methylation to improve alkali–thermal tolerance and yield. Thus, ATT2 is expected to be a potential new post-Green Revolution gene that could be harnessed to develop and use marginal lands for sustainable agriculture in the future. Precise regulation of the phytohormone gibberellin to optimal levels may not only confer alkali–thermal tolerance to Green Revolution rice varieties but may also further enhance their yield, and ATT2 , by enabling the fine-tuning of gibberellins, is expected to be a potential new post-Green Revolution gene.

Background This study aimed to assess the efficacy and safety of transarterial chemoembolization (TACE) in combination with apatinib (TACE-apatinib) for patients with unresectable hepatocellular carcinoma (HCC). Methods This study was a multicenter, randomized, open-label, prospective, phase III trial. Patients with unresectable HCC were randomly assigned in a 1:1 ratio to receive either TACE-apatinib or TACE-alone treatment. Patients in the TACE-apatinib group began with a dosage of 500 mg/day of oral apatinib administered 4 days after the first TACE. The primary endpoint of this study was progression-free survival (PFS). The secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), time to untreatable (unTACEable) progression (TTUP), and safety assessment. Results From November 1, 2018 to November 18, 2021, a total of 196 patients were randomly assigned to either the TACE-apatinib ( n  = 86) or TACE-alone ( n  = 92) group. The median PFS in the TACE-apatinib group was significantly longer than that of in the TACE-alone group (6.1 months vs. 3.4 months, p  < 0.0001). The median OS was significantly prolonged in the TACE-apatinib group compared to the TACE-alone group (28.9 months vs. 24.0 months, p  = 0.0005). The median TTUP in the TACE-apatinib group was 26.8 months, which was significantly longer than that of 20.1 months in the TACE-alone group ( p  = 0.0003). A significantly higher ORR and DCR were observed in the TACE-apatinib group compared to the TACE-alone group (ORR: 58.1% vs. 31.5%, p  < 0.001; DCR: 87.2% vs. 69.6%, p  = 0.004). Most of the treatment-related adverse events were grades 1–2, and no treatment-related deaths were observed. Conclusions Apatinib significantly improved the treatment effects of TACE for patients with unresectable HCC. TACE-apatinib could serve as a promising treatment option for this patient population, offering notable survival benefits while maintaining an acceptable safety profile. Trial registration Chinese Clinical Trial Register, No. ChiCTR1800018621.